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Original Article

Phase Ib/II study combining tosedostat with capecitabine in
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Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited
therapeutic options. We evaluated the safety and efficacy of the aminopeptidase inhibitor tosedostat with
capecitabine in advanced PDAC.
Methods: We conducted a phase Ib/II trial of tosedostat with capecitabine as second-line therapy for
advanced PDAC. Planned enrollment was 36 patients. Eligible patients were treated with capecitabine
1,000 mg/m2 oral twice-daily days 1–14 and oral tosedostat in a dose de-escalation design on days 1–21 of
each 21-day cycle. Primary endpoints were the recommended phase 2 dose (RP2D) and progression-free
survival (PFS).
Results: Sixteen patients were enrolled. Tosedostat 120 mg oral twice daily with capecitabine 1,000 mg/m2
oral twice daily was the RP2D. There was one dose-limiting toxicity (DLT) (grade 3 acute coronary
syndrome) during phase Ib. The most common treatment-related adverse events were gastrointestinal (nausea,
diarrhea), cardiac [QTc prolongation, decreased ejection fraction (EF)], and fatigue. The median PFS was
7.1 months, and the median treatment failure free survival was 3 months. Eight patients experienced stable
disease for greater than 3 months. The study was closed early due to lack of drug availability.
Conclusions: Tosedostat with capecitabine displayed tolerable toxicity, and prolonged disease control in
a subset of patients. These data encourage further exploration of aminopeptidase inhibitors in pancreatic
cancer.
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Introduction
Approximately 55,000 new cases of pancreatic ductal
adenocarcinoma (PDAC) are diagnosed annually in the
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United States. PDAC is projected to be the second leading
cause of cancer-related death by 2030 (1). Current standard
therapies for metastatic PDAC include FOLFIRINOX
(5-FU/LV, irinotecan, oxaliplatin) with median overall
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survival (mOS) of 11.1 months (2), and gemcitabine/
nab-paclitaxel with mOS 8.5 months (3). Given the
considerable toxicity of FOLFIRINOX, a large percentage
of patients with advanced PDAC receive gemcitabine-based
regimens in the front-line setting. Five-FU/leucovorin
(LV)/nanoliposomal-irinotecan (nal-IRI) is a second-line
treatment option for patients who have progressed on a
gemcitabine-based regimen, however median progressionfree survival (PFS) is modest at 3.1 months (4). Thus, there
is great need for more effective regimens in the second or
later lines of therapy.
Aminopeptidases are N-terminus directed peptidases that
degrade peptides resulting from proteasomal degradation
into free single amino acids, and are over-expressed in
multiple malignancies where they provide a continual
supply of free amino acids to support anabolic processes and
cellular growth. Multiple aminopeptidases are expressed in
most cells, including aminopeptidase N (APN), leukotriene
A4 (LTA4) hydrolase, puromycin-sensitive aminopeptidase
(PuSA) and leucine aminopeptidase (LAP) [reviewed in (5)].
Amino acid starvation or treatment with small molecule
aminopeptidase inhibitors leads to depletion of the
cellular free amino acid pool and inhibition of the mTOR
(mammalian target of rapamycin) pathway, as well as a
signature transcriptional response to up-regulate expression
of genes involved in de novo amino acid biosynthesis;
collectively, this constitutes the amino acid deprivation
stress response (AADR) (6).
Notably, aminopeptidase N (APN) is over-expressed in
PDAC relative to benign pancreatic tissue, and higher expression
levels of APN correlate with inferior overall survival (7,8). The
aminopeptidase inhibitor tosedostat (CTI BioPharma, Seattle)
has produced encouraging results in relapsed/refractory acute
myeloid leukemia (AML) (9), and has been evaluated in a phase
I study of advanced solid tumors demonstrating tolerability
and preliminary efficacy, with 4 out of 40 patients experiencing
stable disease for greater than 6 months, and one with renal
cell carcinoma (RCC) experiencing a partial response (10).
Given the high frequency of aminopeptidase over-expression in
PDAC, and its correlation with poorer outcomes, we conducted
a phase Ib/II trial combining tosedostat with capecitabine as a
second-line regimen.
Methods
Study design and participants
This was a single center open-label phase Ib/II study in
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patients with locally advanced or metastatic PDAC to
evaluate the safety and efficacy of tosedostat in combination
with capecitabine. The study was conducted at Washington
University in St. Louis, St. Louis MO, USA. All subjects
gave their informed consent for inclusion before they
participated in the study. The study was conducted in
accordance with the Declaration of Helsinki, and the
protocol was approved by the Ethics Committee of
Washington University in St. Louis. Patients eligible for
enrollment were at least 18 years of age, had histologically
or cytologically proven metastatic or unresectable
PDAC, and had progressed on or were intolerant of prior
gemcitabine-based therapy. Inclusion criteria required
ECOG performance status of 0–2, and adequate bone
marrow and organ function [ANC >1,000/µL, platelets
>100,000/µL, total bilirubin ≤2 mg/dL, creatinine
≤2 mg/dL, AST or ALT ≤2.5× ULN (≤5× ULN in the
setting of liver metastases)]. Exclusion criteria included
prior chemotherapy or radiotherapy within two weeks
of study entry, known brain metastases, prior treatment
with aminopeptidase inhibitor, known dihydropyrimidine
dehydrogenase deficiency (DPD), significant cardiovascular
disease or known HIV positivity on combination antiretroviral therapy. The study protocol was approved by the
Washington University Institutional Review Board (IRB
#201503074), and all patients provided written informed
consent. The study outcomes will not affect the future
management of the patients involved.
Procedures
Tosedostat is an oral drug, which was taken on an outpatient
basis daily on a 21-day cycle, at approximately the same
time every day with food. Dosing of tosedostat during the
phase Ib (lead-in phase) followed a 3+3 dose de-escalation
design beginning with tosedostat 120 mg oral twice daily
(dose level 0) on days 1–21 of each 21-day cycle. Previous
studies identified a maximum tolerated dose (MTD) of
tosedostat of 320 mg daily, and 240 mg as the maximum
accepted dose (10). As there are no significant overlapping
toxicities between tosedostat and capecitabine, a dose of
tosedostat 120 mg oral twice daily was chosen as the entry
dose level. In the event of dose-limiting toxicity (DLT) at
dose level 0, tosedostat was to be dose-reduced to 60 mg
twice daily (dose level 1); no further dose-reductions were
allowed. Capecitabine dosing began at the standard dose
of 1,000 mg/m2 twice daily (dose level 0) on days 1–14 of
each 21-day cycle. For adverse events that were deemed
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Outcomes

Table 1 Characteristics of the patients at baseline
Characteristics
Age, median [range]

N=16

The primary endpoint of the phase Ib was the RP2D of the
combination therapy. For the phase II portion of the study,
the primary endpoint was the PFS of the combination
therapy.

66 [42–73]

Sex, n (%)
Male

7 (43.8)

Female

9 (56.3)

Statistical analysis

Ethnicity, n (%)
Caucasian
African American

OS was defined as the months from the date of treatment
start to date of death. Alive patients were censored at the
last known date of follow up. OS was estimated by the
Kaplan-Meier method and the survival probabilities at some
time points were provided. Treatment failure free survival
(TFFS) duration was defined as the months from the date
of treatment start to the date of treatment end; patients
without related AE or withdrawal were censored at the date
of treatment end. PFS was defined as the months from the
date of treatment start to the date of progression; patients
without progression were censored at the last known date of
follow up. The initial study design planned for 36 patients,
with a power of 0.8 to identify an increase of median PFS
from 2 to 4 months at 0.05 significance level, assuming
12 months of accrual and 6 months of follow-up.

15 (93.8)
1 (6.3)

ECOG PS, n (%)
0

1 (6.3)

1

15 (93.8)

2

0

Prior systemic therapy, n (%)
Gemcitabine

1 (6.3)

Gemcitabine/nab-pac*

6 (37.0)

Gemcitabine/nab-pac/indoximod

5 (31.0)

Gemcitabine/nab-pac/radiation

1 (6.3)

Gemcitabine/nab-pac/VS4718

1 (6.3)

Gemcitabine/nab-pac followed by 5-FU/XRT**

1 (6.3)

CA19-9, mean [min, max]

63

1,255 [1–8,803]

Percentages might not total 100% due to rounding. *Nab-pac,
nanoparticle albumin-bound paclitaxel; **XRT, radiation.

related to capecitabine, dose reduction to 750 mg/m 2
twice daily (dose level 1) and 500 mg/m 2 twice daily
(dose level 2) were allowed. Dose re-escalation was not
allowed. No pre-medications were required for either
tosedostat or capecitabine. Toxicity monitoring by complete
blood count (CBC) and comprehensive metabolic panel
(CMP), and cardiac monitoring by troponin I or T, brain
natriuretic peptide (BNP), electrocardiogram (ECG) and
echocardiogram were performed on day 1 of each cycle.
Tumor assessment by CA19-9 tumor marker was performed
on day 1 of each cycle, and computed tomography (CT)
scans were performed at the end of each even-numbered
cycle. Safety assessments were done in compliance with
the Washington University Institutional Data and Safety
Monitoring Plan. The study principal investigator and
research patient coordinator continuously monitored for
serious toxicities on an ongoing basis. Patients were treated
until progression of disease or unacceptable toxicity.
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Results
Between October 2015 and December 2017, 16 patients
were enrolled on our phase Ib/II study of tosedostat with
capecitabine, including six patients in phase Ib (the dose deescalation phase), and 10 patients in the phase II. The trial
was closed to accrual prematurely on 12/20/2017 due to
insufficient funding and drug supply from the manufacturer
(CTI BioPharma). Patient demographics are presented
in Table 1. The median age was 66 years old, with a slight
predominance of female patients. The majority of patients
had an ECOG performance status of 1. Fourteen patients
had metastatic disease, one had locally advanced disease,
and the presence of metastases was unknown for one
patient. Typical sites of metastases were all represented
(liver, omentum, peritoneum, lungs). A total of six patients
were treated at the starting dose level of tosedostat 120mg
twice daily with capecitabine 1,000 mg/m2 twice daily in the
phase Ib portion, and one patient experienced a DLT (grade
3 acute coronary syndrome) (Table 2), thus tosedostat 120mg
twice daily was identified as the RP2D. There were a total
of five grade 3 treatment-related adverse events observed
(acute coronary syndrome, nausea, prolonged QTc interval,

J Gastrointest Oncol 2020;11(1):61-67 | http://dx.doi.org/10.21037/jgo.2019.11.06

64

Grierson et al. Tosedostat plus capecitabine in pancreatic adenocarcinoma

Table 2 Treatment-related toxicities
Toxicity

Grade 1/2 [%]

Grade 3/4 [%]

Any grade [%]

Anemia

2 [12]

–

2 [12]

–

1 [6]

1 [6]

Diarrhea

5 [31]

1 [6]

6 [37]

Nausea

3 [18]

1 [6]

4 [25]

Mucositis

3 [18]

–

3 [18]

Fatigue

3 [18]

1 [6]

4 [25]

Edema

3 [18]

–

3 [18]

QT interval prolongation

3 [18]

1 [6]

4 [25]

Decreased left ventricle ejection fraction

5 [31]

–

5 [31]

Thrombocytopenia

2 [12]

–

2 [12]

Dizziness

2 [12]

–

2 [12]

Maculopapular rash

2 [12]

–

2 [12]

Acute coronary syndrome

The denominator is the total number of patients.

diarrhea, fatigue). Among six patients in the phase Ib part,
three discontinued treatment due to toxicity [grade 3
fatigue, acute MI prior to assessment of treatment response,
and grade 2 decreased ejection fraction (EF)] and three due
to disease progression. One of 10 patients in the phase II
cohort experienced grade-3 toxicity (QTc prolongation);
no grade-4 or -5 toxicities were observed in the phase II
cohort (Table 2). No deaths were attributed to tosedostat.
The study protocol required monitoring of cardiac EF,
mandating holding, dose-reduction or discontinuation of
tosedostat for grade 2 or 3 decreases in LV EF. Including
the patient in the phase Ib cohort, a total of 5 of 16 patients
(31%) came off study due to grade 2 decreased EF, all of
which were asymptomatic and self-resolved with holding
of tosedostat. The average time to worsening of EF was
65 days, and average time to resolution was 30 days.
Figure 1 shows treatment failure free survival (TFFS)
and duration on study. The median TFFS was 3 months,
and eight patients remained on study with stable disease
for greater than 3 months. No radiographic partial (PR) or
complete (CR) responses were observed. Sixty-two percent
of patients (10/16) had a best response of stable disease,
and 11/16 evaluable patients discontinued treatment due
to disease progression. The median PFS was 7.0 months
(Figure 2).
Ultimately, the study was terminated early due to lack
of drug availability. At the time of study termination, all

© Journal of Gastrointestinal Oncology. All rights reserved.

enrolled patients had been removed from study due to
adverse events or disease progression, however 14/16
(87%) of them remained alive receiving subsequent lines
of therapy. mOS was 11.5 months (Figure 3), and median
duration of follow-up was 11.5 months.
Discussion
Patients with advanced or metastatic pancreatic cancer
face limited effective treatment options. The two most
commonly used front-line regimens, gemcitabine/nabpaclitaxel and FOLFIRINOX, yield response rates of 20–
30%, and mOS of 8.5 and 11.1 months (2,3). Gemcitabine/
nab-paclitaxel is less toxic, thus patients are often treated
with front-line gemcitabine-containing regimens. 5-FUbased regimens are often used for patients who progress on
front-line gemcitabine therapy, supported by the superior
efficacy of 5-FU and oxaliplatin (OFF) over best supportive
care (BSC) in this setting (11). However, due to declining
performance status, many patients are unable to receive
oxaliplatin in the second-line setting, often treated with
single-agent 5-FU or capecitabine. Thus, additional nontoxic second-line regimens building on a fluoropyrimidine
backbone are needed along with new molecular targets to
provide meaningful improvements in outcome.
Previous studies have investigated the aminopeptidase
inhibitor tosedostat in elderly patients with relapsed/
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Figure 1 Treatment failure free survival and duration on study. (A) Shown is the treatment failure free survival for all patients; (B) shown
is the duration on study of all patients. Eight patients remained on study with stable disease for greater than 3 months. Treatment was
discontinued for progressive disease (#) or adverse events (*); one patient was censored (^) due to withdrawal of consent.
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Figure 2 Progression free survival. Shown is the progression free
survival of all patients on study.

refractory AML, displaying CR or CR with incomplete
platelet recovery (CRi) in 10% of patients (9). The first-inhuman phase I study of tosedostat monotherapy in advanced
solid tumors demonstrated tolerability and preliminary
efficacy in a subset of patients; however only one patient
had pancreatic adenocarcinoma, precluding any definitive
conclusions regarding its efficacy in this malignancy (10).
To our knowledge, ours is the first study to evaluate an
aminopeptidase inhibitor in combination with standard
chemotherapy in advanced PDAC.
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Based on the phase Ib portion of our study, we identified
the RP2D of tosedostat as 120mg oral twice daily with
capecitabine 1,000 mg/m2 twice daily. The regimen was
tolerable, with no grade-4 or grade-5 toxicities, and some
grade-3 toxicities. However, there was a high incidence
of low-grade asymptomatic decrease in EF, necessitating
removal of 5/16 patients from study. Interestingly, three of
those affected patients had high-normal baseline EF such
that at their nadir, EFs remained in the near low-normal
range, with an average EF decrease of 15%. No patients
experienced congestive heart failure. Importantly, all
occurrences of depressed EF were asymptomatic and selfresolved with holding of therapy. This degree of cardiac
toxicity is milder than that observed in a previous report
of tosedostat in AML, wherein 3/73 patients (4%) were
documented to experience congestive heart failure, where
one patient received a daily dose of tosedostat 120 mg
and two patients received a daily dose of 240 mg (9). At
present, the mechanism of cardiotoxicity due to tosedostat
is unknown. Together, these observations suggest caution is
advised when treating patients with baseline heart disease,
as well as frequent monitoring of patients without known
heart disease.
The combination of tosedostat/capecitabine had
moderate clinical benefit, with no patients experiencing a
complete or partial response. However, the median TFFS
was 3 months and median PFS was 7.0 months. These
outcomes are encouraging for a second-line therapy, given
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a median PFS of approximately 2 months in this setting,
and they approximate that with standard of care first-line
therapy. However, 8/16 patients experienced stable disease
for greater than 3 months while on study. Given the median
PFS of 3.1 months with nanoliposomal irinotecan/5-FU/
leucovorin, and 1.5 months with 5-FU/leucovorin in the
second-line setting as reported in the NAPOLI-1 trial (4),
this suggests that a subset of patients may be particularly
susceptible to aminopeptidase inhibition. However, the
enrollment of only 16 out of a planned 36 patients in our
study presents a limitation to our data, due to early study
closure. Given our small sample size, comparison to other
published data is limited; a study with a larger sample
size would be needed to confirm our findings. Among
the eight patients with prolonged disease control on our
study (greater than 3 months), two patients had an initial
biochemical partial response (greater than 20% decrease
of CA19-9 from baseline). Notably, those patients with
prolonged disease control had variable durations of disease
control on front-line chemotherapy, and three of them had
amongst the highest baseline CA19-9 values, suggesting
that benefit from the regimen is not an artifact of lower
disease burden or general chemotherapy sensitivity; perhaps
they are uniquely sensitive to amino acid deprivation due to
unknown underlying molecular features.
In conclusion, tosedostat in combination with
capecitabine as a second-line treatment had an acceptable
safety profile and displayed signs of efficacy in a subset of
patients with advanced or metastatic PDAC. However, these
conclusions are limited, as enrollment was less than 45%
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